NCT00134680 - Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2000

Primary Completion Date

January 31, 2005

Study Completion Date

July 31, 2005

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Letrozole

Letrozole tablets 2.5 mg by mouth daily

DRUG

Trastuzumab

Weekly trastuzumab (4 mg/kg loading dose given by IV over 90 minutes folowed by 2 mg/kg given by IV weekly over 30 minutes, provided the previous dose was well tolerated.

Trial Locations (4)

20007

Lombardi Cancer Institute, Georgetown University Medical Center, Washington D.C.

27710

Duke University Medical Center, Durham

63110

Siteman Cancer Center, Washington University, St Louis

02115

Dana Farber Cancer Institute, Boston